imipramine has been researched along with Parkinson Disease in 43 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with Parkinson's syndrome whose major symptoms are akinesis, rigidity, inertia, depression, irritability and failure of adaptation rather than tremor appear to benefit in a global way from therapy with imipramine." | 7.64 | Parkinson's syndrome, depression and imipramine. A preliminary report. ( FOWLER, W; MANDELL, AJ; MARKHAM, C, 1961) |
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 5.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| "Tritiated imipramine binding in platelets has been used to evaluate serotonin activity in depression in previous studies." | 3.68 | Tritiated imipramine binding. A peripheral marker for serotonin in Parkinson's disease. ( Coté, L; Lawton, A; Marder, K; Mayeux, R; Sano, M; Stanley, M; Stern, Y; Williams, J, 1991) |
| "Patients with Parkinson's syndrome whose major symptoms are akinesis, rigidity, inertia, depression, irritability and failure of adaptation rather than tremor appear to benefit in a global way from therapy with imipramine." | 3.64 | Parkinson's syndrome, depression and imipramine. A preliminary report. ( FOWLER, W; MANDELL, AJ; MARKHAM, C, 1961) |
| "The most common features of Parkinson's disease (PD) are motor impairments, but many patients also present depression and memory impairment." | 1.62 | Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease. ( Andreatini, R; Da Cunha, C; Hocayen, PAS; Kanazawa, LKS; Miyoshi, E; Takahashi, RN; Vecchia, DD; Vital, MABF; Wendler, E, 2021) |
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 1.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| " The present study indicates that already a moderate lesion of dopaminergic neurons induces "depressive-like" behaviour in animals which is reversed by chronic administration of the antiparkinsonian drug, pramipexole." | 1.40 | Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease. ( Berghauzen-Maciejewska, K; Dziubina, A; Głowacka, U; Kolasiewicz, W; Kuter, K; Ossowska, K; Wardas, J, 2014) |
| "Nine patients 55 to 74 years old with Parkinson's disease were tested before and after treatment with 50 to 225 mg dimepramine fumarate (CIBA G-31406) for about three weeks daily in order to determine the drug's effects on electrodermal responsiveness to a series of unpredictably occurring loud sounds." | 1.26 | Effects of dimepramine fumarate on physiological and cognitive behaviors of Parkinson patients. ( Feldman, RG; Gade, A; Oscar-Berman, M; Saavedra, MA, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (88.37) | 18.7374 |
| 1990's | 1 (2.33) | 18.2507 |
| 2000's | 1 (2.33) | 29.6817 |
| 2010's | 2 (4.65) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Vecchia, DD | 2 |
| Kanazawa, LKS | 2 |
| Wendler, E | 2 |
| Hocayen, PAS | 1 |
| Vital, MABF | 2 |
| Takahashi, RN | 1 |
| Da Cunha, C | 1 |
| Miyoshi, E | 2 |
| Andreatini, R | 2 |
| de Almeida Soares Hocayen, P | 1 |
| Bruginski, E | 1 |
| Campos, FR | 1 |
| Stern, CAJ | 1 |
| Wöhr, M | 1 |
| Schwarting, RKW | 1 |
| Berghauzen-Maciejewska, K | 1 |
| Kuter, K | 1 |
| Kolasiewicz, W | 1 |
| Głowacka, U | 1 |
| Dziubina, A | 1 |
| Ossowska, K | 1 |
| Wardas, J | 1 |
| GAL, JC | 1 |
| DENMARK, JC | 1 |
| DAVID, JD | 1 |
| McCOMB, SG | 1 |
| MANDELL, AJ | 1 |
| MARKHAM, C | 1 |
| FOWLER, W | 1 |
| SIGWALD, J | 1 |
| PAKKENBERG, H | 1 |
| GILLHESPY, RO | 1 |
| MUSTARD, DM | 1 |
| GILLINGHAM, FJ | 1 |
| KALYANARAMAN, S | 1 |
| POROT, M | 1 |
| PASCALIS, G | 1 |
| LIM, H | 1 |
| TAN, K | 1 |
| Winer, JA | 1 |
| Bahn, S | 1 |
| Edwards, M | 1 |
| Okiishi, CG | 1 |
| Paradiso, S | 1 |
| Robinson, RG | 1 |
| Oscar-Berman, M | 1 |
| Gade, A | 1 |
| Feldman, RG | 1 |
| Saavedra, MA | 1 |
| Bhaskar, PA | 1 |
| Bhaskar, EA | 1 |
| Jagannathan, K | 1 |
| Sano, M | 1 |
| Stanley, M | 1 |
| Lawton, A | 1 |
| Coté, L | 1 |
| Williams, J | 1 |
| Stern, Y | 1 |
| Marder, K | 1 |
| Mayeux, R | 2 |
| Schneider, LS | 1 |
| Chui, HC | 1 |
| Severson, JA | 1 |
| Sloane, RB | 1 |
| Raisman, R | 1 |
| Cash, R | 1 |
| Agid, Y | 1 |
| Suranyi-Cadotte, BE | 1 |
| Gauthier, S | 1 |
| Lafaille, F | 1 |
| DeFlores, S | 1 |
| Dam, TV | 1 |
| Nair, NP | 1 |
| Quirion, R | 1 |
| D'Amato, RJ | 1 |
| Zweig, RM | 1 |
| Whitehouse, PJ | 1 |
| Wenk, GL | 1 |
| Singer, HS | 1 |
| Price, DL | 1 |
| Snyder, SH | 1 |
| Klawans, HL | 1 |
| Carvey, PM | 1 |
| Tanner, CM | 1 |
| Goetz, CG | 1 |
| Jenkins, RB | 2 |
| Groh, RH | 2 |
| Chase, TN | 1 |
| Nelson, SR | 1 |
| Walaszek, EJ | 1 |
| Roos, BE | 1 |
| Shibasaki, H | 1 |
| Shibazaki, H | 1 |
| Debus, G | 1 |
| Markham, CH | 1 |
| Giroud, M | 1 |
| Flandrois, R | 1 |
| Calamai, M | 1 |
| Buffat, JJ | 1 |
| Quiviger, P | 1 |
| Mouret, JR | 1 |
| Fisher, C | 1 |
| Yahr, MD | 1 |
| Duvoisin, RC | 1 |
| Tolosa, E | 1 |
| Presthus, J | 1 |
| Schmidt, P | 1 |
| Castaigne, P | 1 |
| Laplane, D | 1 |
| Dordain, G | 1 |
| Birkmayer, W | 1 |
| Kirow, K | 1 |
| Dandiya, PC | 1 |
| Bhargava, LP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Kinetic Studies in Whole Body and Brain of [11C]DASB PET Imaging of Serotonin Transporters[NCT00059046] | 20 participants | Observational | 2003-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for imipramine and Parkinson Disease
| Article | Year |
|---|---|
Gender differences in depression associated with neurologic illness: clinical correlates and pharmacologic response.
Topics: Alzheimer Disease; Amitriptyline; Antidepressive Agents, Tricyclic; Depression; Epilepsy; Female; Hu | 2001 |
Serotonergic mechanisms and extrapyramidal function in man.
Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extr | 1974 |
Pharmacology of the central nervous system.
Topics: Abnormalities, Drug-Induced; Acetylcholine; Adrenocorticotropic Hormone; Amphetamine; Anger; Angiote | 1968 |
Parkinson's syndrome. Recent progress in the medical treatment and its pharmacological basis.
Topics: Amantadine; Atropine; Catecholamines; Dihydroxyphenylalanine; Histamine H1 Antagonists; Humans; Imip | 1971 |
[Recent advances and pharmacological basis of the medical treatment of Parkinson's syndrome].
Topics: Amantadine; Catecholamines; Dihydroxyphenylalanine; Histamine H1 Antagonists; Humans; Imipramine; Pa | 1971 |
Drug therapy of parkinsonism.
Topics: Amantadine; Amitriptyline; Amphetamine; Antiparkinson Agents; Dihydroxyphenylalanine; Drug Antagonis | 1972 |
Parkinson's disease; modern treatment.
Topics: Amantadine; Amphetamine; Antidepressive Agents; Antiparkinson Agents; Aromatic Amino Acid Decarboxyl | 1973 |
[Other trials with drug therapy in parkinsonism].
Topics: 5-Hydroxytryptophan; Amitriptyline; Animals; Dihydroxyphenylalanine; Disulfiram; Drug Evaluation; Dr | 1973 |
[Therapy of Parkinsonism. II].
Topics: Amantadine; Amitriptyline; Humans; Imipramine; Levodopa; Parkinson Disease; Physical Therapy Modalit | 1974 |
[On the antagonism between neuroleptic and thymoleptic drugs in psychiatry and neurology].
Topics: Drug Synergism; Humans; Imipramine; Mental Disorders; Parkinson Disease; Tranquilizing Agents | 1965 |
33 other studies available for imipramine and Parkinson Disease
| Article | Year |
|---|---|
Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Imipramine; Ketamine; Male; Memory, S | 2021 |
Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease.
Topics: Anhedonia; Animals; Depression; Disease Models, Animal; Gait; Imipramine; Ketamine; Male; Nerve Dege | 2018 |
Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease.
Topics: Animals; Antidepressive Agents; Benzothiazoles; Depression; Disease Models, Animal; Dopamine Agonist | 2014 |
[Study of the action of imipramine on parkinsonian akinesia].
Topics: Apraxias; Imipramine; Parkinson Disease; Psychopharmacology | 1960 |
Imipramine hydrochloride (Tofranil) in Parkinsonism. A preliminary report.
Topics: Imipramine; Parkinson Disease; Parkinsonian Disorders; Psychopharmacology | 1961 |
Parkinson's syndrome, depression and imipramine. A preliminary report.
Topics: Depression; Depressive Disorder; Humans; Imipramine; Irritable Mood; Motivation; Muscle Rigidity; Pa | 1961 |
[Treatment of parkinsonian akinesia].
Topics: Apraxias; Humans; Imipramine; Iproniazid; Monoamine Oxidase Inhibitors; Parkinson Disease | 1961 |
[Pathogenesis and medical treatment of parkinsonism].
Topics: Humans; Imipramine; Parkinson Disease; Parkinsonian Disorders; Piperidines; Trihexyphenidyl | 1963 |
The evaluation of imipramine in the treatment of Parkinson's disease.
Topics: Humans; Imipramine; Parasympatholytics; Parkinson Disease | 1963 |
PARKINSON'S DISEASE.
Topics: Amitriptyline; Dextroamphetamine; Humans; Imipramine; Muscle Relaxants, Central; Neurosurgery; Orphe | 1963 |
[Neurological complications during imipramine therapy].
Topics: Basal Ganglia Diseases; Disease; Extrapyramidal Tracts; Imipramine; Nervous System Diseases; Parkins | 1959 |
[Treatment of Parkinson syndroms with tofranil].
Topics: Humans; Imipramine; Parkinson Disease; Parkinsonian Disorders | 1961 |
Loss of teeth with antidepressant drug therapy.
Topics: Dental Caries; Diphenhydramine; Humans; Imipramine; Male; Middle Aged; Parkinson Disease; Psychophar | 1967 |
Adverse interaction of levodopa with tricyclic antidepressants.
Topics: Aged; Amitriptyline; Carbidopa; Drug Combinations; Drug Interactions; Female; Humans; Imipramine; Le | 1982 |
Effects of dimepramine fumarate on physiological and cognitive behaviors of Parkinson patients.
Topics: Aged; Antiparkinson Agents; Cognition; Female; Galvanic Skin Response; Habituation, Psychophysiologi | 1979 |
Augmenting procedures during L-dopa therapy for Parkinsonism.
Topics: Antacids; Dextroamphetamine; Drug Synergism; Female; Humans; Imipramine; Levodopa; Male; Middle Aged | 1975 |
Tritiated imipramine binding. A peripheral marker for serotonin in Parkinson's disease.
Topics: Aged; Biomarkers; Blood Platelets; Depression; Humans; Hydroxyindoleacetic Acid; Imipramine; Middle | 1991 |
Decreased platelet 3H-imipramine binding in Parkinson's disease.
Topics: Aged; Blood Platelets; Carrier Proteins; Depressive Disorder; Female; Humans; Imipramine; Male; Park | 1988 |
Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen.
Topics: Aged; Binding Sites; Humans; Imipramine; Middle Aged; Parkinson Disease; Paroxetine; Piperidines; Pu | 1986 |
Platelet 3H-imipramine binding distinguishes depression from Alzheimer dementia.
Topics: Age Factors; Aged; Alzheimer Disease; Blood Platelets; Carrier Proteins; Depressive Disorder; Diagno | 1985 |
Aminergic systems in Alzheimer's disease and Parkinson's disease.
Topics: Alzheimer Disease; Biogenic Amines; Brain; Choline O-Acetyltransferase; Citalopram; Humans; Imiprami | 1987 |
Drug-induced myoclonus.
Topics: 5-Hydroxytryptophan; Anesthetics; Animals; Anti-Bacterial Agents; Antidepressive Agents; Bismuth; Ca | 1986 |
Mental symptoms in Parkinsonian patients treated with L-dopa.
Topics: Aged; Behavior; Depression; Dihydroxyphenylalanine; Dreams; Female; Humans; Imipramine; Male; Memory | 1970 |
[Parkinson's syndrome. 10. Effects of psychopharmacological agents on central monoamine neurons].
Topics: Amitriptyline; Humans; Imipramine; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Reserpi | 1970 |
[Self- and foreign placements of current condition in psychopharmacological longitudinal studies].
Topics: Adolescent; Aggression; Alcoholism; Antiparkinson Agents; Anxiety; Depression; Drug Evaluation; Extr | 1974 |
The "on-off" side effect of L-DOPA.
Topics: Age Factors; Amitriptyline; Aromatic Amino Acid Decarboxylase Inhibitors; Athetosis; Carbidopa; Cate | 1974 |
[Primary alveolar hypoventilation, Ondine's curse. New aspects of functional exploration. Study of ventilatory regulation and disorders of wakefulness].
Topics: Adult; Carbon Dioxide; Diabetes Insipidus; Electrocardiography; Encephalitis; Feeding and Eating Dis | 1974 |
[Imipramine in parkinsonism].
Topics: Aged; Drug Evaluation; Female; Humans; Imipramine; Male; Middle Aged; Parkinson Disease | 1973 |
[Amantadine. Prolonged clinical trial in 50 parkinsonian patients].
Topics: Adult; Aged; Amantadine; Dihydroxyphenylalanine; Drug Synergism; Female; Humans; Imipramine; Male; M | 1972 |
[Conservative therapy in the Parkinson syndrome].
Topics: Amantadine; Antidepressive Agents; Dihydroxyphenylalanine; Humans; Imipramine; Injections, Intraveno | 1971 |
Psychic effects in patients treated with levodopa.
Topics: Aged; Depression; Dihydroxyphenylalanine; Female; Humans; Imipramine; Middle Aged; Parkinson Disease | 1970 |
[Treatment of Parkinsonian syndromes with two derivates of iminodibenzil: imipramine (tofranil) and desipramine (pertrofana)].
Topics: Aged; Desipramine; Female; Humans; Imipramine; Male; Middle Aged; Parkinson Disease | 1967 |
The antiparkinsonian activity of monoamine oxidase inhibitors and other agents in rats and mice.
Topics: Animals; Dextroamphetamine; Diphenhydramine; Imipramine; Iproniazid; Isocarboxazid; Mice; Monoamine | 1968 |